Shares of Biora Therapeutics, Inc. (NASDAQ:BIOR – Get Free Report) fell 14.2% during trading on Monday . The stock traded as low as $0.15 and last traded at $0.16. 5,826 shares were traded during trading, a decline of 90% from the average session volume of 58,319 shares. The stock had previously closed at $0.19.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their price target on shares of Biora Therapeutics from $15.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, November 18th.
View Our Latest Research Report on BIOR
Biora Therapeutics Stock Performance
Biora Therapeutics Company Profile
Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
See Also
- Five stocks we like better than Biora Therapeutics
- What Are Dividend Achievers? An Introduction
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- 3 Grocery Stocks That Are Proving They Are Still Essential
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- What is the S&P/TSX Index?
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.